Relationship Details

This document appears to be page 52 of a confidential partnership agreement or offering memorandum, marked with a House Oversight control number. It outlines governance mechanisms for an investment fund, including liability insurance coverage, the recall of distributions, 'Key Person' clauses triggered by the loss of Principals, and voting thresholds for Limited Partners to terminate the investment period or remove the General Partner. The text defines specific percentages (85%, 66 2/3%) required for investor actions against the fund management.

This document appears to be page 69 of a confidential offering memorandum or private placement memorandum for an investment fund. It outlines risk factors related to liquidity and reliance on projections, defines industry terminology regarding 'general partners' and the legal structure of the fund, and discloses that neither the Fund nor the General Partner is registered under the Investment Company Act of 1940 or the Securities Exchange Act of 1934. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it is part of a congressional investigation.

Page 78 of a confidential financial offering document (likely a PPM) describing U.S. federal income tax consequences for investors ('Partners') in 'The Fund.' The text details complex regulations regarding Controlled Foreign Corporations (CFCs), the applicability of U.S. Foreign Tax Credits for taxes paid in other jurisdictions, and the tax treatment of Foreign Currency gains and losses. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a congressional investigation.

This document appears to be page 65 of a confidential offering memorandum or similar financial disclosure document for an investment fund. It details specific risk factors and strategies, including leverage risks, investments in public companies, hedging techniques (specifically 'selling short against the box'), portfolio trading policies, and risks associated with non-U.S. investments. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it is part of a congressional investigation.

This document appears to be page 56 of a confidential Offering Memorandum or Private Placement Memorandum for an investment fund found in the House Oversight Committee's files. It details legal and tax considerations for three specific types of investors: ERISA plans (retirement funds), U.S. tax-exempt investors, and non-U.S. investors. The text outlines the General Partner's obligations to manage the fund in a way that minimizes adverse tax consequences, such as Unrelated Business Taxable Income (UBTI) or creating a taxable trade presence in the United States.

This document is page 81 of a confidential legal document, likely a Private Placement Memorandum (PPM) for an investment fund. It details tax consequences for investors, specifically focusing on currency conversion issues for Non-U.S. Partners, withholding taxes (FATCA) on foreign entities, and state/local tax liabilities. The document bears a 'HOUSE_OVERSIGHT' stamp, indicating it was part of a congressional investigation.

This document is page 75 of a confidential offering memorandum or partnership agreement, marked with a House Oversight control number. It details the tax implications for both tax-exempt and taxable U.S. partners in an investment fund, specifically addressing Unrelated Business Taxable Income (UBTI), limitations on deductions (Section 67 and 68 of the Code), and the 3.8% surtax on unearned income (Section 1411). It outlines the obligations of the General Partner to mitigate tax liabilities for investors.

This document is page 62 of a confidential offering memorandum (likely a Private Placement Memorandum) for a fund identified as 'NLV-III'. It outlines significant risk factors for potential investors, including the illiquidity of investments, the lack of operating history for the newly formed Fund and General Partner, the lack of assurance regarding profits or distributions, and the highly competitive nature of venture capital investments. The document bears a House Oversight Committee stamp, indicating it is part of a congressional investigation.

This document appears to be page 61 of a confidential private placement memorandum or risk disclosure statement for a biopharmaceutical investment fund. It outlines risks related to healthcare legislation (Medicare/Medicaid), the availability of investment capital for portfolio companies, and general economic market risks. The document bears a House Oversight Committee Bates stamp, suggesting it was obtained during a congressional investigation, likely related to financial entities connected to Jeffrey Epstein.

This is page 85 of a confidential Private Placement Memorandum (PPM) obtained by the House Oversight Committee (Bates stamp HOUSE_OVERSIGHT_024096). It details legal and regulatory considerations for an unnamed 'Fund,' specifically focusing on exemptions from the Securities Act of 1933 and the Investment Company Act of 1940. Crucially, it discloses that the General Partner is not registered as a broker-dealer with the NASD or under the Exchange Act.